Inhibition of HIV protease by monoclonal antibodies

Journal of Molecular Recognition

Volumn 15, Issue 5, 2002, Pages 272-276

  Rezacova, P ^a   Brynda, J ^a   Fabry, M ^a   Horejsi, M ^a   Stouracova, R ^a   Lescar, J ^b   Chitarra, V ^c   Riottot, M M ^c   Sedlacek, J ^a   Bentley, G A ^c  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c INSTITUT PASTEUR   (France)

Author keywords

Crystal structure; Enzyme inhibition; HIV protease; Monoclonal antibodies

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; PROTEINASE; PROTEINASE INHIBITOR;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; IN VITRO STUDY; MOUSE; PROTEIN CONFORMATION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION;

EID: 0036760474     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.587     Document Type: Article

References (23)

1. AI-Lazikani B, Lesk AM, Chothia C. 1997. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273: 927-948.
2. Babé LM, Rosé J, Craik CS. 1992. Synthetic 'interface' peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci. 1: 1244-1253.
3. Holzman TF, Kolhbrenner WE, Weigl D, Rittenhouse J, Kempf D, Erickson J. 1991. Inhibitor stabilisation of Human Immunoldeficiency Virus type-2 proteinase dimer formation. J. Biol. Chem. 266: 19217-19220.
4. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. 1991. Sequences of Proteins of Immunological Interest, 5th Edn. US Department of Health and Human Services, NIH: Bethesda, MD.
5. Katz RA, Skalka AM. 1994. The retroviral enzymes. A. Rev. Biochem. 63: 133-173.
6. Köhler G, Milstein C. 1975. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
7. Lescar J, Stouracova R, Riottot MM, Chitarra V, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA. 1996. Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity. Protein Sci. 5: 966-968.
8. Lescar J, Stouracova R, Riottot MM, Chitarra V, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA. 1997. Three-dimensional structure of an Fab-peptide complex: Structural basis of HIV-1 protease inhibition by a monoclonal antibody. J. Mol. Biol. 267: 1207-1222.
9. Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA. 1999. Protein Sci. 8: 2686-2696.
10. Murali R, Sharkey DJ, Daiss JL, Murthy HMK. 1998. Crystal structure of Taq DNA polymerase in complex with an inhibitory Fab: The Fab is directed against an intermediate in the helix-coil dynamics of the enzyme. Proc. Natl Acad. Sci. USA 95: 12562-12567.
11. Navia MA, Fitzgerald PMD, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL, Springer JP. 1989. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337: 615-620.
12. Rao JKM, Erickson JW, Wlodawer A. 1991. Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 30: 4667-4671.
13. Rezacova P, Lescar J, Brynda J, Fabry M, Horejsi M, Sedlacek J, Bentley GA. 2001. Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody. Structure 9: 887-895.
14. Schramm HJ, Boetzel J, Büttner J, Fritsche E, Görhing W, Jaeger E, König S, Thumfart O, Wenger T, Nagel NE, Schramm W. 1996. The Inhibition of Human Immunodeficiency virus proteases by Interface Peptides. Antiviral Res. 30: 155-170.
15. Stanfield RL, Wilson IA. 1995. Protein-peptide interactions. Curr. Opin. Struct. Biol. 5:103-113.
16. Stanfield RL, Fieser TM, Lerner RA, Wilson IA. 1990. Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 Å. Science 248: 712-719.
17. Tormo J, Blaas D, Parry NR, Rowlands D, Stuart D, Fita I. 1994. Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from the viral capsid protein VP2. EMBO J. 13: 2247-2256.
18. Wien MW, Filman DJ, Stura EA, Guillot S, Delpeyroux F, Crainic R, Hogle JM (1995). Structure of the complex between the Fab fragment of a neutralizing antibody for type 1 poliovirus and its viral epitope. Nat. Struct. Biol. 2: 232-243.
19. Williams JW, Morrison JF. 1979. The kinetics of reversible tight-binding inhibition. In Methods in Enzymology, Purich DL (ed.), Academic Press. Vol. 63: 437-467.
20. Wlodawer A, Miller M, Jakolski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk L, Clawson LM, Schneider J, Kent SBH. 1989. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245: 616-621.
21. Wu TT, Johnson G, Kabat EA. 1993. Length distribution of CDRH3 in antibodies. Proteins Struct. Funct. Genet. 16: 1-7.
22. Zhang ZY, Poorman RA, Maggiora LL, Heinrikson RL, Kézdy FJ. 1991. Dissociative inhibition of dimeric enzymes. J. Biol. Chem. 266: 15591-15594.
23. Zutshi R, Franciskovich J, Shultz M, Scheiter B, Bishop P, Wilson M, Chmielewski J. 1997. Targeting the dimerization interface of HIV-1 protease: Inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc. 119: 4841-4845.